Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	5983	98.9%	93.0%	97.7%	93.5%	95.9%	~
Apr-June	2011	6145	98.4%	92.7%	96.9%	93.1%	95.3%	~
July-Sept	2011	6403	98.5%	92.8%	96.8%	93.5%	95.4%	~
Oct-Dec	2011	6240	98.3%	93.3%	96.9%	94.2%	95.7%	~
Jan-Mar	2012	6182	98.5%	93.7%	97.1%	94.8%	95.9%	~
Apr-June	2012	6148	98.6%	95.3%	97.1%	95.8%	95.7%	~
July-Sept	2012	6505	98.6%	95.4%	97.2%	95.5%	95.7%	~
Oct-Dec	2012	6562	98.7%	95.9%	97.2%	96.4%	96.5%	~
Jan-Mar	2013	6159	98.4%	95.3%	97.1%	95.8%	95.9%	~
Apr-June	2013	6027	98.7%	96.1%	~	96.2%	96.4%	~
July-Sept	2013	6576	98.8%	96.0%	~	95.9%	96.0%	~
Oct-Dec	2013	6260	98.6%	96.3%	~	96.3%	96.5%	~
Jan-Mar	2014	6229	98.5%	96.1%	~	96.1%	96.3%	~
Apr-June	2014	6185	98.9%	96.4%	~	96.2%	96.3%	~
July-Sept	2014	6443	98.7%	96.4%	~	96.8%	96.5%	~
Oct-Dec	2014	6421	98.4%	95.5%	~	95.9%	95.9%	~
Jan-Mar	2015	5816	97.9%	94.5%	~	95.0%	94.7%	~
Apr-June	2015	5914	98.2%	96.1%	~	95.9%	95.8%	~
July-Sept	2015	6466	98.3%	95.8%	~	95.8%	95.8%	~
Oct-Dec	2015	5959	98.3%	95.5%	~	96.0%	95.9%	~
Jan-Mar	2016	5923	98.3%	95.9%	~	96.3%	95.9%	~
Apr-June	2016	5978	97.9%	95.0%	~	95.5%	95.3%	~
July-Sept	2016	6521	97.9%	94.5%	~	94.9%	95.0%	~
Oct-Dec	2016	6162	97.9%	94.8%	~	95.2%	94.9%	~
Jan-Mar	2017	5765	98.0%	94.7%	~	95.0%	94.8%	~
Apr-June	2017	5937	97.9%	94.8%	~	95.1%	95.0%	~
July-Sept	2017	6524	97.9%	94.6%	~	94.9%	94.8%	94.1%
Oct-Dec	2017	6238	97.7%	93.8%	~	94.6%	94.4%	94.1%
Jan-Mar	2017	5781	98.0%	94.6%	~	95.7%	95.0%	94.6%
Apr-June	2018	5995	97.5%	93.4%	~	93.8%	93.7%	93.4%
July-Sept	2018	6363	97.4%	93.6%	~	94.1%	93.9%	93.7%
Oct-Dec	2018	6133	96.9%	92.3%	~	92.5%	93.5%	92.2%
Jan-Mar	2018	5709	96.5%	92.3%	~	92.5%	92.5%	92.2%
Apr-June	2019	5656	95.8%	91.4%	~	91.8%	91.7%	91.4%
•	2019	6140	96.0%				92.2%	92.2%
July-Sept Oct-Dec	2019	5883	96.0%	92.1% 92.7%	~	92.5% 93.5%	92.2%	92.2% 92.6%
	2019	5431		92.7%	~			92.6% 92.1%
Jan-Mar		5806	95.6%		~	92.6%	92.3%	
Apr-June	2020	6080	95.5%	92.2%	~	92.6%	92.2%	92.3%
July-Sept	2020	5743	95.8%	91.9%	~	92.3%	92.1%	91.8%
Oct-Dec	2020		96.0%	92.3%	~	92.7%	92.5%	92.2%
Jan-Mar	2021	5451	96.2%	91.5%	~	92.0%	91.7%	91.2%
Apr-June	2021	5549	95.9%	92.4%	~	92.9%	92.6%	91.9%
July-Sept	2021	5993	95.4%	91.1%	~	91.5%	91.5%	90.5%
Oct-Dec	2021	5651	94.7%	91.3%	~	91.5%	91.3%	90.4%
Jan-Mar	2022	5315	95.2%	91.9%	~	92.0%	92.0%	91.3%
Apr-June	2022	5272	94.4%	90.5%	~	90.6%	90.6%	89.5%
July-Sept	2022	5731	94.0%	89.4%	~	89.6%	89.5%	88.9%
Oct-Dec	2022	5434	94.4%	89.5%	~	90.2%	89.8%	89.0%
Jan-Mar	2023	5384	94.0%	89.4%	~	91.8%	89.8%	89.2%
Apr-June	2023	5342	93.8%	89.3%	~	89.8%	89.8%	88.6%
Jul-Sept	2023	6007	93.1%	88.8%	~	89.1%	89.0%	88.1%
Oct-Dec	2023	5646	93.7%	89.5%	~	89.7%	89.7%	88.7%
Jan-Mar	2024	5159	93.6%	89.3%	~	89.4%	89.4%	88.3%
Apr-June	2024	5117	93.6%	89.9%	~	90.0%	90.1%	89.0%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 =
Tet3 =
Pert3 =
Pol (IPV)3 =
Hib3 =
HepB3 =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

33 = Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2
pB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

MMR1 = Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)
MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in BHSCT: Completed Primary Immunisations by 24 months

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1086	98.2%	88.8%	96.1%	88.6%	92.6%	~
Apr-June	2011	1141	97.1%	88.9%	94.7%	89.8%	92.4%	~
July-Sept	2011	1185	96.6%	88.5%	94.3%	89.5%	91.9%	~
Oct-Dec	2011	1153	96.4%	89.4%	95.1%	89.9%	92.5%	~
Jan-Mar	2012	1066	97.4%	89.7%	94.6%	90.4%	92.5%	~
Apr-June	2012	1141	98.1%	92.8%	95.7%	92.7%	93.1%	~
July-Sept	2012	1218	96.9%	92.5%	94.6%	92.2%	92.5%	~
Oct-Dec	2012	1313	97.3%	93.6%	94.5%	94.0%	94.1%	~
Jan-Mar	2013	1158	97.4%	93.1%	94.8%	93.3%	93.8%	~
Apr-June	2013	1092	97.8%	93.7%	~	93.5%	93.4%	~
July-Sept	2013	1264	97.9%	94.9%	~	94.2%	94.0%	~
Oct-Dec	2013	1214	97.2%	93.7%	~	92.6%	93.3%	~
Jan-Mar	2014	1228	97.0%	93.7%	~	93.2%	93.5%	~
Apr-June	2014	1163	98.1%	94.5%	~	93.4%	94.0%	~
July-Sept	2014	1211	97.2%	94.0%	~	95.2%	93.9%	~
Oct-Dec	2014	1218	97.0%	93.5%	~	93.4%	93.1%	~
Jan-Mar	2015	1111	96.0%	90.9%	~	91.9%	91.0%	~
Apr-June	2015	1115	96.3%	93.1%	~	92.6%	92.3%	~
July-Sept	2015	1258	97.0%	93.7%	~	93.2%	93.3%	~
Oct-Dec	2015	1118	96.1%	91.8%	~	91.8%	91.6%	~
Jan-Mar	2015	1097	97.1%	93.6%	~	93.7%	93.5%	~
Apr-June	2016	1155	96.6%	91.6%	~	91.8%	91.6%	~
July-Sept	2016	1190	96.5%	90.0%	~	90.4%	90.0%	~
Oct-Dec	2016	1145		90.0% 89.8%	~	90.4%	90.0% 89.8%	~
			95.3%		~			
Jan-Mar	2017	1105	96.5%	90.6%		90.5%	90.0%	~
Apr-June	2017	1121	95.9%	92.3%	~	92.1%	91.9%	~
July-Sept	2017	1151	96.4%	91.3%	~	91.1%	90.4%	90.0%
Oct-Dec	2017	1127	95.0%	88.7%	~	89.1%	89.0%	88.3%
Jan-Mar	2018	1058	95.8%	91.4%	~	91.6%	91.2%	91.1%
Apr-June	2018	1091	95.1%	89.2%	~	89.5%	88.9%	88.9%
July-Sept	2018	1161	95.1%	89.0%	~	88.8%	88.5%	88.2%
Oct-Dec	2018	1194	94.9%	86.8%	~	86.9%	86.9%	86.3%
Jan-Mar	2019	1046	93.9%	85.3%	~	86.3%	85.5%	85.4%
Apr-June	2019	995	90.3%	82.8%	~	83.7%	83.0%	83.0%
July-Sept	2019	1086	92.1%	84.9%	~	85.5%	85.0%	85.1%
Oct-Dec	2019	1080	91.7%	87.2%	~	87.4%	86.8%	86.6%
Jan-Mar	2020	1014	91.9%	86.0%	~	87.0%	85.7%	86.0%
Apr-June	2020	1057	92.2%	86.7%	~	87.1%	86.1%	86.0%
July-Sept	2020	1161	92.5%	85.5%	~	85.6%	85.1%	85.3%
Oct-Dec	2020	1067	93.1%	87.9%	~	88.3%	88.1%	87.6%
Jan-Mar	2021	986	93.4%	85.2%	~	85.3%	84.6%	83.3%
Apr-June	2021	1053	93.2%	86.1%	~	87.0%	86.2%	84.8%
July-Sept	2021	1127	92.4%	83.4%	~	83.8%	83.8%	82.2%
Oct-Dec	2021	1055	90.0%	84.1%	~	83.8%	84.0%	82.4%
Jan-Mar	2022	983	90.8%	85.0%	~	84.2%	84.8%	83.2%
Apr-June	2022	1005	89.1%	81.1%	~	81.1%	80.7%	78.7%
July-Sept	2022	1083	88.6%	81.1%	~	80.6%	80.7%	79.1%
Oct-Dec	2022	1015	88.5%	80.0%	~	79.6%	80.1%	77.6%
Jan-Mar	2023	1015	87.8%	79.8%	~	90.4%	80.2%	78.3%
Apr-June	2023	960	86.1%	79.0%	~	78.9%	79.0%	75.6%
Jul-Sept	2023	1113	88.8%	82.8%	~	82.4%	82.3%	80.0%
Oct-Dec	2023	1056	88.3%	82.5%	~	82.2%	82.7%	80.2%
Jan-Mar	2024	891	89.0%	84.6%	~	83.8%	84.0%	81.0%
Apr-June	2024	924	89.9%	84.8%	~	85.0%	85.0%	82.3%
, .p. 00.10		J	00.070	0 / 0		00.070	00.070	02.070

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = Hib3 = HepB3 =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar

Infant MenC = PCV Booster = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) <u>reporting ceased in April 2013</u> Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

Measles, mumps, and rubella vaccine (1 dose)
Hib/MenC booster vaccine (1 dose) (introduced September 2006)
Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015) MMR1 = Hib/MenC =

MenB3 =

Vaccination Coverage Statistics for Children in SEHSCT: Completed Primary Immunisations by 24 months

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1066	98.4%	91.3%	97.3%	92.4%	94.7%	~
Apr-June	2011	1157	98.1%	91.4%	96.9%	91.8%	94.4%	~
July-Sept	2011	1226	98.5%	92.4%	97.0%	93.6%	95.6%	~
Oct-Dec	2011	1132	97.7%	92.8%	96.5%	94.2%	95.1%	~
Jan-Mar	2012	1096	98.6%	93.8%	97.7%	94.3%	95.3%	~
Apr-June	2012	1113	98.4%	95.0%	97.2%	95.6%	95.5%	~
July-Sept	2012	1190	98.7%	95.1%	97.6%	95.5%	95.9%	~
Oct-Dec	2012	1183	98.7%	95.9%	97.6%	96.3%	96.1%	~
Jan-Mar	2012	1077	98.1%	95.7%	97.0%	96.4%	96.4%	~
Apr-June	2013	1120	99.0%	96.3%	~	96.3%	96.9%	~
July-Sept	2013	1231	98.4%	95.7%		95.9%	96.3%	~
Oct-Dec	2013	1147	98.8%	96.7%	~ ~	97.6%	90.3%	~
Jan-Mar	2014	1154	99.0%	97.2%	~	97.9%	98.2%	~
Apr-June	2014	1106	99.2%	96.0%	~	96.1%	96.1%	~
July-Sept	2014	1110	98.6%	96.2%	~	96.3%	96.4%	~
Oct-Dec	2014	1158	99.2%	96.7%	~	97.8%	97.2%	~
Jan-Mar	2015	1082	97.0%	94.5%	~	94.8%	94.7%	~
Apr-June	2015	1092	98.5%	96.6%	~	96.4%	96.2%	~
July-Sept	2015	1157	98.9%	96.1%	~	95.9%	95.9%	~
Oct-Dec	2015	1028	98.2%	95.6%	~	96.3%	96.1%	~
Jan-Mar	2016	1082	98.4%	95.6%	~	95.7%	95.6%	~
Apr-June	2016	1070	97.9%	95.5%	~	96.3%	96.3%	~
July-Sept	2016	1201	97.9%	94.6%	~	95.3%	95.6%	~
Oct-Dec	2016	1085	98.0%	95.4%	~	96.2%	96.2%	~
Jan-Mar	2017	1028	98.0%	94.9%	~	94.7%	94.4%	~
Apr-June	2017	1078	97.2%	94.0%	~	95.1%	94.2%	~
July-Sept	2017	1217	97.9%	95.5%	~	95.9%	95.4%	95.5%
Oct-Dec	2017	1115	98.4%	95.2%	~	96.1%	95.6%	95.5%
Jan-Mar	2017	1049	98.3%	95.2%	~	95.3%	95.0%	94.9%
Apr-June	2018	1097	97.4%	92.9%	~	93.5%	93.7%	93.6%
July-Sept	2018	1166	97.7%	93.7%	~	94.1%	93.7%	93.8%
Oct-Dec	2018	1063	97.1%	93.7%	~	93.9%	93.7%	93.5%
Jan-Mar	2019	1056	96.7%	92.2%	~	92.9%	92.9%	92.8%
Apr-June	2019	976	96.2%	93.9%	~	93.5%	93.3%	93.8%
July-Sept	2019	1027	96.4%	93.7%	~	94.0%	94.2%	94.0%
Oct-Dec	2019	1053	96.6%	93.8%	~	93.8%	93.5%	93.7%
Jan-Mar	2020	975	95.9%	93.3%	~	93.9%	93.6%	93.6%
Apr-June	2020	1041	95.8%	92.3%	~	93.1%	92.4%	92.6%
July-Sept	2020	1101	95.6%	92.3%	~	92.9%	92.6%	92.3%
Oct-Dec	2020	1036	97.4%	93.0%	~	93.1%	93.0%	92.9%
Jan-Mar	2021	961	95.5%	91.1%	~	91.6%	91.1%	90.5%
Apr-June	2021	1007	95.5%	91.6%	~	92.4%	92.0%	91.5%
July-Sept	2021	1061	95.3%	89.8%	~	90.4%	90.0%	89.1%
Oct-Dec	2021	967	94.3%	90.3%	~	90.3%	90.1%	88.3%
Jan-Mar	2021	960	95.5%	90.7%	~	91.3%	91.1%	90.3%
Apr-June	2022	907		90.7%	~	91.5%	91.1%	
	2022	907 1024	93.6%					90.0%
July-Sept			92.5%	88.2%	~	88.3%	88.3%	87.4%
Oct-Dec	2022	931	93.3%	88.1%	~	88.3%	88.3%	87.3%
Jan-Mar	2023	920	93.0%	89.6%	~	89.9%	90.0%	89.7%
Apr-June	2023	963	92.2%	88.0%	~	88.7%	88.6%	87.4%
Jul-Sept	2023	1042	91.1%	87.6%	~	87.7%	87.5%	86.7%
Oct-Dec	2023	1013	93.5%	89.8%	~	89.7%	89.9%	88.9%
Jan-Mar	2024	948	90.7%	87.2%	~	87.7%	87.3%	86.2%
	2024	895	93.3%	89.8%	~	89.2%	89.3%	87.9%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = Hib3 = HepB3 =

Infant MenC =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013 Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over MMR1 = Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)

MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in NHSCT: Completed Primary Immunisations by 24 months

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1377	99.5%	94.9%	98.3%	95.4%	97.4%	~
Apr-June	2011	1438	98.4%	93.7%	97.0%	94.1%	96.6%	~
July-Sept	2011	1498	99.2%	93.7%	98.0%	94.6%	96.1%	~
Oct-Dec	2011	1487	98.9%	93.4%	97.6%	94.8%	96.4%	~
Jan-Mar	2012	1550	98.5%	94.5%	97.1%	95.9%	96.8%	~
Apr-June	2012	1510	99.1%	96.3%	97.5%	97.0%	96.9%	~
July-Sept	2012	1544	98.8%	95.1%	97.6%	95.3%	95.5%	~
Oct-Dec	2012	1565	99.2%	96.6%	98.0%	97.1%	97.1%	~
Jan-Mar	2013	1490	98.8%	95.1%	97.7%	95.8%	96.2%	~
Apr-June	2013	1477	98.8%	96.4%	~	96.6%	96.5%	~
July-Sept	2013	1550	99.0%	96.2%	~	96.1%	96.3%	~
Oct-Dec	2013	1455	99.0%	97.0%	~	97.3%	97.5%	~
Jan-Mar	2014	1466	98.6%	95.6%	~	96.2%	96.3%	~
Apr-June	2014	1456	98.6%	95.5%	~	96.1%	95.9%	~
July-Sept	2014	1553	99.0%	97.1%	~	97.4%	97.1%	~
Oct-Dec	2014	1536	98.6%	95.0%	~	96.2%	96.4%	~
Jan-Mar	2015	1408	99.1%	93.6%	~	94.9%	94.7%	~
Apr-June	2015	1442	98.2%	96.0%	~	96.0%	96.1%	~
July-Sept	2015	1558	98.3%	96.7%	~	96.5%	96.7%	~
Oct-Dec	2015	1448	98.8%	96.5%	~	97.3%	97.2%	~
Jan-Mar	2016	1429	98.5%	96.4%	~	97.5%	96.7%	~
Apr-June	2016	1393	98.3%	96.6%	~	96.8%	96.7%	~
July-Sept	2016	1571	98.2%	95.4%	~	96.1%	96.2%	~
Oct-Dec	2016	1515	98.7%	95.6%	~	95.9%	95.8%	~
Jan-Mar	2017	1391	98.3%	95.3%	~	95.9%	95.8%	~
Apr-June	2017	1443	99.2%	95.4%	~	96.1%	96.0%	~
July-Sept	2017	1541	98.4%	94.4%	~	94.9%	95.2%	94.2%
Oct-Dec	2017	1490	98.5%	95.2%	~	96.0%	96.0%	95.3%
Jan-Mar	2018	1328	98.9%	95.7%	~	96.8%	96.7%	96.2%
Apr-June	2018	1430	98.0%	94.4%	~	95.4%	95.0%	94.9%
July-Sept	2018	1506	97.9%	95.8%	~	96.5%	96.3%	96.1%
Oct-Dec	2018	1487	97.6%	93.5%	~	93.7%	93.8%	93.5%
Jan-Mar	2019	1371	97.1%	92.6%	~	93.2%	93.1%	93.0%
Apr-June	2019	1343	97.2%	93.0%	~	93.4%	93.4%	93.2%
July-Sept	2019	1505	97.3%	94.1%	~	94.3%	94.4%	94.0%
Oct-Dec	2019	1398	97.4%	95.1%	~	95.6%	95.6%	95.1%
Jan-Mar	2020	1239	96.8%	93.5%	~	93.6%	93.5%	93.3%
Apr-June	2020	1380	96.7%	94.3%	~	95.0%	94.5%	94.6%
July-Sept	2020	1396	96.8%	94.1%	~	94.8%	94.8%	94.5%
Oct-Dec	2020	1355	96.5%	93.7%	~	93.9%	93.8%	93.4%
Jan-Mar	2021	1309	97.3%	93.4%	~	94.1%	94.1%	93.9%
Apr-June	2021	1314	97.6%	95.0%	~	95.7%	95.5%	95.1%
July-Sept	2021	1427	97.1%	93.9%	~	94.3%	94.5%	93.7%
Oct-Dec	2021	1366	96.6%	93.3%	~	93.6%	93.6%	92.5%
Jan-Mar	2022	1229	96.7%	94.1%	~	94.4%	94.5%	93.7%
Apr-June	2022	1302	96.2%	92.7%	~	93.0%	93.1%	92.5%
.'			96.3%				92.5%	
July-Sept Oct-Dec	2022 2022	1392 1264	98.1%	92.2% 93.7%	~	92.6% 94.1%	93.8%	92.0% 93.8%
Jan-Mar	2022	1276	95.7%	90.7%	~	91.3%	91.3%	91.1%
Apr-June	2023	1300	96.8%	92.8%	~	93.5%	93.6%	92.7%
Jul-Sept	2023	1387	95.2%	91.3%		91.8%	91.9%	91.3%
Oct-Dec	2023	1333	95.2% 95.1%	90.5%	~	91.1%	91.9%	90.9%
					~			
Jan-Mar	2024	1243	96.3% 95.0%	91.1%	~	91.2% 92.2%	91.4%	90.9%
Apr-June	2024	1231	90.0%	92.0%	~	92.2%	92.6%	91.3%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 =
Tet3 =
Pert3 =
Pol (IPV)3 =
Hib3 =
HepB3 =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

MMR1 = Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)

MenB3 = Hib/MenC booster vaccine (1 dose) (introduced September 2005)

Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in SHSCT: Completed Primary Immunisations by 24 months

	uarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Ja	an-Mar	2011	1367	99.4%	94.1%	98.7%	94.4%	97.0%	~
Ap	or-June	2011	1391	99.5%	94.5%	98.0%	94.8%	96.6%	~
Jul	ly-Sept	2011	1415	98.7%	94.3%	96.9%	94.3%	96.8%	~
Or	ct-Dec	2011	1417	98.9%	95.1%	97.2%	95.3%	96.6%	~
Ja	an-Mar	2012	1410	99.1%	94.8%	97.7%	95.7%	96.5%	~
Ap	or-June	2012	1356	98.8%	96.5%	96.8%	96.8%	96.8%	~
	ly-Sept	2012	1474	99.1%	97.1%	97.4%	97.0%	97.0%	~
	ct-Dec	2012	1440	99.2%	96.7%	98.1%	96.9%	97.4%	~
Ja	an-Mar	2013	1369	98.8%	96.2%	97.7%	96.4%	96.1%	~
	or-June	2013	1291	98.8%	96.6%	~	96.7%	97.1%	~
	ly-Sept	2013	1447	99.0%	96.2%	~	96.0%	96.3%	~
	ct-Dec	2013	1389	99.1%	96.7%	~	96.5%	96.5%	~
	an-Mar	2014	1357	99.1%	96.8%	~	96.6%	96.6%	~
	or-June	2014	1424	98.9%	97.4%	~	97.1%	97.3%	~
	ly-Sept	2014	1542	99.0%	97.5%	~	97.3%	97.4%	~
	ct-Dec	2014	1430	98.6%	95.9%	~	95.5%	95.9%	~
	an-Mar	2015	1314	98.6%	96.7%	~	96.2%	96.3%	~
	or-June	2015	1329	98.9%	97.5%	~	96.8%	97.0%	~
	ly-Sept	2015	1420	98.7%	96.3%	~	96.4%	96.3%	~
	ct-Dec	2015	1377	99.1%	96.4%	~	96.8%	96.7%	~
	an-Mar	2016	1360	99.0%	97.7%	~	97.0%	97.2%	~
	or-June	2016	1389	98.1%	95.6%	~	95.7%	96.0%	~
	ly-Sept	2016	1437	98.2%	95.8%	~	95.7 % 95.2%	95.5%	~
	ct-Dec	2016	1403	98.4%	96.5%	~	95.6%	95.7%	~
	an-Mar	2017	1319	98.4%	96.7%	~	96.9%	96.8%	~
		2017	1322				95.8%	96.1%	
	or-June		1501	98.4%	96.3%	~			~ 94.2%
	ly-Sept	2017	1458	97.9%	95.1%	~	95.1%	95.4% 95.2%	
	ct-Dec	2017	1369	98.1%	94.9%	~	95.3%		95.1%
	an-Mar	2018		98.2%	94.7%	~	94.8%	95.3%	94.5%
	or-June	2018	1381	98.7%	95.6%	~	94.6%	94.9%	94.1%
	ly-Sept	2018	1466	97.5%	94.1%	~	94.3%	94.3%	93.9%
	ct-Dec	2018	1398	97.3%	93.9%	~	94.1%	94.3%	93.6%
	an-Mar	2019	1274	97.2%	92.8%	~	93.2%	93.1%	92.6%
	or-June	2019	1383	97.2%	94.2%	~	94.2%	94.1%	94.1%
	ly-Sept	2019	1501	96.8%	93.9%	~	94.0%	93.7%	93.7%
	ct-Dec	2019	1317	97.3%	94.2%	~	94.2%	94.0%	93.8%
	an-Mar	2020	1263	97.1%	94.2%	~	94.4%	94.6%	93.6%
	or-June	2020	1353	95.8%	93.1%	~	93.1%	93.3%	93.3%
	ly-Sept	2020	1435	96.2%	93.2%	~	93.0%	92.7%	92.1%
	ct-Dec	2020	1360	96.5%	93.2%	~	93.2%	93.1%	92.9%
	an-Mar	2021	1259	96.9%	93.8%	~	94.3%	94.0%	93.6%
	or-June	2021	1290	95.9%	93.7%	~	93.5%	93.3%	92.6%
	ly-Sept	2021	1413	96.2%	92.8%	~	92.9%	93.2%	92.2%
	ct-Dec	2021	1344	95.9%	93.1%	~	93.3%	93.2%	92.9%
	an-Mar	2022	1218	96.6%	93.8%	~	94.4%	93.8%	93.4%
	or-June	2022	1172	95.9%	92.2%	~	92.3%	91.9%	91.5%
	ly-Sept	2022	1308	96.0%	91.6%	~	91.7%	91.6%	91.2%
	ct-Dec	2022	1251	95.3%	91.4%	~	91.7%	91.8%	91.3%
	an-Mar	2023	1244	96.9%	93.5%	~	93.7%	93.5%	93.4%
	or-June	2023	1230	96.4%	93.0%	~	93.0%	92.6%	92.4%
	ul-Sept	2023	1435	94.9%	89.5%	~	90.0%	89.8%	89.5%
_	ct-Dec	2023	1319	95.4%	91.7%	~	91.7%	91.7%	90.6%
Ja	an-Mar or-June	2024 2024	1232 1227	95.3% 95.0%	91.6% 91.0%	~	91.8% 91.0%	92.0% 91.1%	91.3% 90.9%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = Hib3 = HepB3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Ma

Infant MenC = PCV Booster = MMR1 = Hib/MenC =

Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC booster vaccine (1 dose) (introduced September 2006)

[~] Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1087	98.7%	95.3%	97.5%	96.0%	96.9%	~
Apr-June	2011	1018	98.9%	94.4%	97.5%	94.8%	95.8%	~
July-Sept	2011	1079	99.1%	94.9%	97.8%	95.5%	96.5%	~
Oct-Dec	2011	1051	99.1%	95.8%	97.8%	96.6%	97.5%	~
Jan-Mar	2012	1060	99.0%	95.3%	98.2%	97.0%	97.9%	~
Apr-June	2012	1028	98.7%	95.7%	98.1%	96.0%	95.7%	~
July-Sept	2012	1079	99.4%	97.1%	99.0%	97.5%	97.6%	~
Oct-Dec	2012	1061	99.1%	96.8%	97.9%	98.0%	97.9%	~
Jan-Mar	2013	1065	99.0%	96.6%	98.1%	97.0%	97.0%	~
Apr-June	2013	1047	98.9%	97.2%	~	97.8%	97.9%	~
July-Sept	2013	1084	99.4%	97.4%	~	97.3%	97.0%	~
Oct-Dec	2013	1055	98.8%	97.3%	~	97.4%	97.6%	~
Jan-Mar	2013	1024	98.8%	97.3%	~	97.0%	96.9%	~
		1036						
Apr-June	2014		99.8%	98.8%	~	98.6%	98.6%	~
July-Sept	2014	1027	99.6%	97.0%	~	97.5%	97.3%	~
Oct-Dec	2014	1079	98.5%	96.7%	~	96.8%	97.1%	~
Jan-Mar	2015	901	98.6%	97.1%	~	97.3%	97.1%	~
Apr-June	2015	936	98.8%	97.2%	~	97.6%	97.4%	~
July-Sept	2015	1073	99.1%	96.2%	~	96.8%	96.8%	~
Oct-Dec	2015	988	99.1%	96.8%	~	97.5%	97.4%	~
Jan-Mar	2016	955	98.3%	95.8%	~	98.1%	96.5%	~
Apr-June	2016	971	98.2%	95.6%	~	97.0%	95.9%	~
July-Sept	2016	1122	98.7%	96.4%	~	97.1%	97.1%	~
Oct-Dec	2016	1014	98.8%	96.1%	~	98.2%	96.8%	~
Jan-Mar	2017	922	98.6%	95.9%	~	96.5%	96.4%	~
Apr-June	2017	973	98.4%	95.7%	~	96.3%	96.3%	~
July-Sept	2017	1114	98.7%	96.8%	~	97.4%	97.5%	96.8%
Oct-Dec	2017	1048	98.1%	94.5%	~	96.0%	95.5%	95.9%
Jan-Mar	2018	977	98.6%	95.5%	~	96.6%	96.5%	96.0%
Apr-June	2018	996	97.9%	94.3%	~	95.6%	95.3%	94.8%
July-Sept	2018	1064	98.6%	94.8%	~	96.1%	96.3%	95.9%
Oct-Dec	2018	991	97.4%	93.3%	~	93.8%	93.5%	93.8%
Jan-Mar	2019	962	97.5%	92.3%	~	96.9%	93.0%	92.4%
Apr-June	2019	959	97.0%	91.4%	~	92.5%	92.3%	92.5%
July-Sept	2019	1021	96.4%	92.8%	~	93.4%	92.8%	93.1%
Oct-Dec	2019	1035	96.6%	92.0%	~	95.6%	92.9%	92.6%
Jan-Mar	2020	940	95.6%	93.3%	~	93.4%	93.4%	93.3%
Apr-June	2020	975	96.7%	94.2%	~	94.1%	93.8%	94.4%
July-Sept	2020	987	97.7%	94.2%	~	95.1%	94.9%	94.8%
Oct-Dec	2020	925	96.4%	93.4%	~	94.5%	94.4%	94.1%
Jan-Mar	2020	936	97.2%	92.8%	~	93.5%	93.3%	93.2%
Apr-June	2021	885	96.8%	95.1%	~	95.6%	95.6%	95.1%
July-Sept	2021	965	95.8%	94.8%	~	95.9%	95.4%	94.8%
Oct-Dec	2021	919	95.9%	95.0%	~	95.5%	95.4%	95.1%
Jan-Mar	2021	925			~		95.2%	95.1%
			95.9%	95.0%		94.7%		
Apr-June	2022	886	97.0%	94.6%	~	94.8%	95.0%	94.1%
July-Sept	2022	924	95.8%	93.4%	~	94.3%	93.8%	93.7%
Oct-Dec	2022	973	95.7%	93.1%	~	96.3%	93.5%	93.3%
Jan-Mar	2023	929	95.4%	92.5%	~	93.2%	93.2%	92.5%
Apr-June	2023	889	96.0%	91.7%	~	92.9%	93.3%	92.6%
Jul-Sept	2023	1030	94.8%	92.0%	~	92.9%	92.6%	92.1%
Oct-Dec	2023	925	95.8%	92.3%	~	93.2%	92.6%	92.3%
Jan-Mar	2024	845	95.0%	90.4%	~	91.0%	90.8%	90.2%
Apr-June	2024	840	93.6%	90.7%	~	91.4%	91.4%	91.3%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Dip3 = Tet3 = Pert3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020 Pol (IPV)3 = Hib3 =

HepB3 =

~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) <u>reporting ceased in April 2013</u> Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006) Infant MenC =

PCV Booster =

MMR1 = Measles, mumps, and rubella vaccine (1 dose) Hib/MenC booster vaccine (1 dose) (introduced September 2006)

Hib/MenC =

MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)